Stay updated on Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe screenshots show additional history entries for NCT01169337 on the Study Record History page, extending the version history with newer submission dates. These updates are routine record-keeping and do not alter core study information or page functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check37 days agoChange DetectedPage now includes a government-operating-status notice and a new revision tag (v3.2.0), replacing the old revision (v3.0.2).SummaryDifference1%

- Check44 days agoChange DetectedUpdated page now includes a current date and a new Study Status Contacts/Locations section, while an older date (2025-09-10) was removed.SummaryDifference0.1%

- Check51 days agoChange Detected- Updated revision label from v3.0.1 to v3.0.2. - Removal of a Back to Top element. Overall, this is a minor, non-substantive update focused on versioning and navigation rather than core content or functionality.SummaryDifference0.1%

- Check58 days agoChange DetectedMajor data-model upgrade: adds facility/location data and a large set of Study Status/Contacts-Locations entries, removes legacy location fields, and bumps revision to v3.0.1.SummaryDifference100%

- Check83 days agoChange DetectedThe web page has been updated to a new version, v2.16.12, with the previous version, v2.16.11, being removed. Additionally, a date of 2025-08-11 has been added.SummaryDifference0.7%

Stay in the know with updates to Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide vs Observation in High-Risk Smoldering Myeloma Clinical Trial page.